Riskpilot← Back to searchSign inGet full accessARTBIO AS
ASActiveOrg 920749453Gaustadalléen 21, 0349 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 201821 employees
Revenue 2024
NOK 74,3M
+23% vs 2023
EBITDA margin
11.2%
-17% vs 2023
Equity ratio
42.7%
Financial strength
Net profit 2024
NOK 8,2M
-30% vs 2023
| Revenue | NOK 74,3M | +23% |
| EBITDA | NOK 8,3M | -17% |
| Net profit | NOK 8,2M | -30% |
| Total assets | NOK 53,9M | +86% |
| Equity | NOK 23M | +34% |
| Employees | 21 | — |
Legal name
ARTBIO AS
Org number
920749453
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
19. april 2018
Share capital
NOK 228 600
Employees
21 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Utvikle markedsføre og selge medisinske produkter og utstyr samt det som står i forbindelse med dette.
Address
Gaustadalléen 21, 0349 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 154 | 1 399 | 1 143 | 1 910 | 25 797 | 60 439 | 74 293 |
| Staff expenses | −263 | −677 | −677 | −1 353 | −0 | −0 | −0 |
| EBITDA | −476 | −1 465 | −3 583 | −6 582 | −14 674 | 10 026 | 8 334 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −476 | −1 465 | −3 583 | −6 582 | −14 674 | 10 026 | 8 334 |
| Net financials | 2 | 5 | 18 | −13 | 44 | 1 728 | −120 |
| Profit before tax | −474 | −1 461 | −3 566 | −6 595 | −14 630 | 11 755 | 8 214 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −474 | −1 461 | −3 566 | −6 595 | −14 630 | 11 755 | 8 214 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 8 137 | 8 195 | 3 915 | 24 254 | 21 428 | 28 964 | 53 898 |
| Equity | 8 056 | 6 595 | 3 029 | 20 269 | 5 638 | 17 199 | 23 037 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 81 | 1 600 | 886 | 3 985 | 15 789 | 11 764 | 30 861 |
| Total debt | 81 | 1 600 | 886 | 3 985 | 15 789 | 11 764 | 30 861 |
EBITDA margin
11.2%
This company
15.8%
Market median
-29% vs market
20182024
Equity ratio
42.7%
This company
38.2%
Market median
+12% vs market
20182024
Return on equity
35.7%
This company
18.4%
Market median
+94% vs market
20182024
Net profit margin
11.1%
This company
8.1%
Market median
+37% vs market
20182024
Asset turnover
1.38×
This company
1.12×
Market median
+23% vs market
20182024
Debt / equity
1.34×
This company
0.62×
Market median
-116% vs market
20182024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-03-19 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MR Observer | Observer | 2022 | — | — |
GF Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
ØS Observer | Observer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Artbio Inc | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ARTBIO AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Martin Russell Gareth Taylor | Observer | 0 companies |
| Gjermund Fjeld Olsen | Chief Executive Officer | 0 companies |
| Øyvind Sverre Bruland | Observer | 0 companies |
| Roy Hartvig Larsen | Chairman | 0 companies |
| Anders Tuv | Board of Directors | 0 companies |
| Emanuele Ostuni | Chairman | 0 companies |
| Calvin Jeong Woon Lee | Board of Directors | 0 companies |
| Jonas Einarsson | Board of Directors | 0 companies |
| Alexander Thomas Pasteur | Board of Directors | 0 companies |